Monthly
US$200
Billed every month
Sign in to subscribeAs of 16 November 2026, for Levocetirizine dihydrochloride Oral Solution, 5 applications are listed as under review at China's CDE; 2 companies have filed new generic applications in 2026; the chemical-drug catalogue lists 0 holders.
Companies, stages and changes, with each record available on this page.
Listed in the US FDA Orange Book as XYZAL ALLERGY 24HR (NDA 209090, CHATTEM INC DBA SANOFI CONSUMER HEALTHCARE).
Last 90 days: Accepted: 4 applicationsNo longer listed under review: 2 applicationsSupplement delivery: 2 applications
Current coverage may be incomplete
Free: up to 3 drugs, Monday digest. Sign in with Google or an email code. No card needed.
The brand names come from the US FDA Orange Book and describe US listing records for this active ingredient. They do not indicate that products under these brand names are approved or sold in China, or that Chinese applicants are affiliated with US holders.
Orange Book source export date: 2026/11/06. Version: 2026-11-06.
Showing 2 of 2 distinct brand names.
A brand with different source forms or statuses can appear on multiple rows and in both groups. Distinct brand names are counted once globally, with a limit of five.
Verified official English dosage form: Oral Solution. Listings are grouped by the source dosage form and route; records without a clear correspondence are listed in the other group. Grouping does not establish product equivalence.
| Brand name | Applicant (source text) | Application number | Dosage form (source text) | Route (source text) | Marketing status (source text) | Approval date |
|---|---|---|---|---|---|---|
| XYZAL ALLERGY 24HR | CHATTEM INC DBA SANOFI CONSUMER HEALTHCARE | NDA 209090 · Product no. 001 | SOLUTION | ORAL | HUMAN OTC DRUG | 2017/01/31 |
| XYZAL | CHATTEM INC DBA SANOFI CONSUMER HEALTHCARE | NDA 022157 · Product no. 001 | SOLUTION | ORAL | DISCONTINUED | 2008/01/28 |
| Brand name | Applicant (source text) | Application number | Dosage form (source text) | Route (source text) | Marketing status (source text) | Approval date |
|---|---|---|---|---|---|---|
| XYZAL ALLERGY 24HR | CHATTEM INC DBA SANOFI CONSUMER HEALTHCARE | NDA 209089 · Product no. 001 | TABLET | ORAL | HUMAN OTC DRUG | 2017/01/31 |
| XYZAL | CHATTEM INC DBA SANOFI CONSUMER HEALTHCARE | NDA 022064 · Product no. 001 | TABLET | ORAL | DISCONTINUED | 2007/05/25 |
Same-form/route listings come first, followed by other forms/routes. Within each group, source prescription/OTC listings precede discontinued listings; unknown statuses are last. Each status bucket is ordered by earliest approval date, ascending: pre-1982 records first, missing dates last; ties by brand name, application number and product number. The first five distinct brands in this order are selected globally. All retained source facts for those brands are shown in their own groups; a brand spanning both groups counts once.
Each source is counted separately. Expand a list to inspect companies, identifiers, dates and sources.
Legal reference identifiers are retained verbatim. Company labels use official English entries where available, or a visibly marked fixed romanization. Unverified drug names retain the Chinese source name with a No verified English name marker. Other Chinese free text is not displayed; use the source links or source-name columns in CSV exports.
Loaded records: 0 holders; 0 in the quality-and-efficacy consistency-evaluation category, and 0 in the new chemical-registration-classification generic category. Category counts may overlap.
| Marketing authorization holder | Manufacturer | Approval number | Approved | Strength / specification | Catalogue category (source text) | View source |
|---|---|---|---|---|---|---|
| No matching records were found in the currently loaded source data; coverage dates are listed below. | ||||||
Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
Loaded records: 35 distinct approval numbers and 26 companies.
| Company / applicant | Approval number | Strength / specification | NHSA class | NHSA drug code | View source |
|---|---|---|---|---|---|
| Beijing Han Mei Medicines Co., Ltd. romanized | 国药准字H20183008 | 75ml:37.5mg | Category B | XR06AEZ066X001010100041 | NHSA |
| Beijing SL Pharmaceutical Co., Ltd. | 国药准字H20264048 | 75ml:37.5mg | Category B | XR06AEZ066X001010100148 | NHSA |
| Beijing Bai Ya Joint Drug Research Institute Co., Ltd. romanized | 国药准字H20223049 | 0.05%(150ml:75mg) | Category B | XR06AEZ066X001010100371 | NHSA |
| Chongqing Huapont Pharmaceutical Co., Ltd. | 国药准字H20061289 | 10ml:5mg | Category B | XR06AEZ066X001010101003 | NHSA |
| Changzhou Si Yao Pharmaceutical Co., Ltd. romanized | 国药准字H20244915 | 150ml:75mg | Category B | XR06AEZ066X001010101389 | NHSA |
| Jiangsu Han Chen Pharma Co., Ltd. romanized | 国药准字H20183398 | 10ml:5mg | Category B | XR06AEZ066X001010101442 | NHSA |
| Yangtze River Pharmaceutical Group Co., Ltd | 国药准字H20223535 | 0.05%(150ml:75mg) | Category B | XR06AEZ066X001010101747 | NHSA |
| Sichuan Da Zhong Pharmaceutical Co., Ltd. romanized | 国药准字H20203222 | 0.05%(150ml:75mg) | Category B | XR06AEZ066X001010102132 | NHSA |
| Ya Bao Pharma Sichuan Pharmaceutical Co., Ltd. romanized | 国药准字H20265412 | 75ml:37.5mg | Category B | XR06AEZ066X001010102281 | NHSA |
| Henan Tong Yuan Pharmaceutical Co., Ltd. romanized | 国药准字H20183319 | 10ml∶5mg | Category B | XR06AEZ066X001010103008 | NHSA |
| Jilin Sheng Hui Nan Chang Long Sheng Hua Pharma Co., Ltd. romanized | 国药准字H20253785 | 10ml:5mg | Category B | XR06AEZ066X001010103421 | NHSA |
| Zhejiang He Li Xin Jian Pharma Co., Ltd. romanized | 国药准字H20223974 | 0.05%(150ml:75mg) | Category B | XR06AEZ066X001010104670 | NHSA |
| Xiamen Zi Xu Pharmaceuticals Technology Co., Ltd. romanized | 国药准字H20213134 | 0.05%(150ml:75mg) | Category B | XR06AEZ066X001010104828 | NHSA |
| Hunan Jiudian Pharmaceutical Co., Ltd | 国药准字H20183089 | 10ml:5mg | Category B | XR06AEZ066X001010104942 | NHSA |
| Hainan Si Da Pharmaceutical Co., Ltd. romanized | 国药准字H20255137 | 150ml:75mg | Category B | XR06AEZ066X001010105816 | NHSA |
| Hua Yi Tai Kang Pharma Co., Ltd. romanized | 国药准字H20183155 | 0.05%(10ml:5mg) | Category B | XR06AEZ066X001010105819 | NHSA |
| Hubei Wei Sen Pharmaceutical Co., Ltd. romanized | 国药准字H20244952 | 75ml:37.5mg | Category B | XR06AEZ066X001010106673 | NHSA |
| Fu An Pharma Group Hubei Ren Min Pharmaceutical Co., Ltd. romanized | 国药准字H20234579 | 0.05%(75ml:37.5mg) | Category B | XR06AEZ066X001010109554 | NHSA |
| Bei Da Pharmaceuticals Co., Ltd. romanized | 国药准字H20244194 | 5ml:2.5mg | Category B | XR06AEZ066X001010109586 | NHSA |
| Chongqing Sheng Kai Pharmaceutical Co., Ltd. romanized | 国药准字H20253351 | 75ml:37.5mg | Category B | XR06AEZ066X001010179299 | NHSA |
| Beijing Cheng Ji Pharmaceutical Co., Ltd. romanized | 国药准字H20183108 | 10ml:5mg | Category B | XR06AEZ066X001010182209 | NHSA |
| Shandong Zhi Tai Pharmaceuticals Technology Co., Ltd. romanized | 国药准字H20254368 | 150ml:75mg | Category B | XR06AEZ066X001010183094 | NHSA |
| Anhui Si Huan Ke Bao Pharmaceutical Co., Ltd. romanized | 国药准字H20264891 | 2.5ml:1.25mg | Category B | XR06AEZ066X001010183595 | NHSA |
| Hefei Guo Gao Pharma Co., Ltd. romanized | 国药准字H20265446 | 75ml:37.5mg | Category B | XR06AEZ066X001010183883 | NHSA |
| Zhejiang Yi Han Pharmaceutical Co., Ltd. romanized | 国药准字H20254365 | 150ml:75mg | Category B | XR06AEZ066X001010184227 | NHSA |
| Beijing Han Mei Bio Technology Co., Ltd. romanized | 国药准字H20254395 | 75ml:37.5mg | Category B | XR06AEZ066X001010184761 | NHSA |
| Chongqing Huapont Pharmaceutical Co., Ltd. | 国药准字H20061289 | 10ml:5mg | Category B | XR06AEZ066X001010201003 | NHSA |
| Henan Tong Yuan Pharmaceutical Co., Ltd. romanized | 国药准字H20183319 | 10ml∶5mg | Category B | XR06AEZ066X001010203008 | NHSA |
| Xiamen Zi Xu Pharmaceuticals Technology Co., Ltd. romanized | 国药准字H20213133 | 0.05%(75ml:37.5mg) | Category B | XR06AEZ066X001010204828 | NHSA |
| Hunan Jiudian Pharmaceutical Co., Ltd | 国药准字H20183089 | 10ml:5mg | Category B | XR06AEZ066X001010204942 | NHSA |
| Hua Yi Tai Kang Pharma Co., Ltd. romanized | 国药准字H20183155 | 0.05%(10ml:5mg) | Category B | XR06AEZ066X001010205819 | NHSA |
| Bei Da Pharmaceuticals Co., Ltd. romanized | 国药准字H20244194 | 5ml:2.5mg | Category B | XR06AEZ066X001010209586 | NHSA |
| Beijing Cheng Ji Pharmaceutical Co., Ltd. romanized | 国药准字H20183108 | 10ml:5mg | Category B | XR06AEZ066X001010282209 | NHSA |
| Anhui Si Huan Ke Bao Pharmaceutical Co., Ltd. romanized | 国药准字H20264891 | 2.5ml:1.25mg | Category B | XR06AEZ066X001010283595 | NHSA |
| Henan Tong Yuan Pharmaceutical Co., Ltd. romanized | 国药准字H20183319 | 10ml∶5mg | Category B | XR06AEZ066X001010303008 | NHSA |
| Hunan Jiudian Pharmaceutical Co., Ltd | 国药准字H20183089 | 10ml:5mg | Category B | XR06AEZ066X001010304942 | NHSA |
| Beijing Cheng Ji Pharmaceutical Co., Ltd. romanized | 国药准字H20183108 | 10ml:5mg | Category B | XR06AEZ066X001010382209 | NHSA |
| Anhui Si Huan Ke Bao Pharmaceutical Co., Ltd. romanized | 国药准字H20264891 | 2.5ml:1.25mg | Category B | XR06AEZ066X001010383595 | NHSA |
| Henan Tong Yuan Pharmaceutical Co., Ltd. romanized | 国药准字H20183319 | 10ml∶5mg | Category B | XR06AEZ066X001010403008 | NHSA |
| Hunan Jiudian Pharmaceutical Co., Ltd | 国药准字H20183089 | 10ml:5mg | Category B | XR06AEZ066X001010404942 | NHSA |
| Beijing Cheng Ji Pharmaceutical Co., Ltd. romanized | 国药准字H20183108 | 10ml:5mg | Category B | XR06AEZ066X001010482209 | NHSA |
| Anhui Si Huan Ke Bao Pharmaceutical Co., Ltd. romanized | 国药准字H20264891 | 2.5ml:1.25mg | Category B | XR06AEZ066X001010483595 | NHSA |
| Henan Tong Yuan Pharmaceutical Co., Ltd. romanized | 国药准字H20183319 | 10ml∶5mg | Category B | XR06AEZ066X001010503008 | NHSA |
| Hunan Jiudian Pharmaceutical Co., Ltd | 国药准字H20183089 | 10ml:5mg | Category B | XR06AEZ066X001010504942 | NHSA |
| Henan Tong Yuan Pharmaceutical Co., Ltd. romanized | 国药准字H20183319 | 10ml∶5mg | Category B | XR06AEZ066X001010603008 | NHSA |
| Hunan Jiudian Pharmaceutical Co., Ltd | 国药准字H20183089 | 10ml:5mg | Category B | XR06AEZ066X001010604942 | NHSA |
| Hunan Jiudian Pharmaceutical Co., Ltd | 国药准字H20183089 | 10ml:5mg | Category B | XR06AEZ066X001010704942 | NHSA |
| Hunan Jiudian Pharmaceutical Co., Ltd | 国药准字H20183089 | 10ml:5mg | Category B | XR06AEZ066X001010804942 | NHSA |
| Hunan Jiudian Pharmaceutical Co., Ltd | 国药准字H20183089 | 10ml:5mg | Category B | XR06AEZ066X001010904942 | NHSA |
| Beijing SL Pharmaceutical Co., Ltd. | 国药准字H20264049 | 200ml:100mg | Category B | XR06AEZ066X001020100148 | NHSA |
| Beijing Bai Ya Joint Drug Research Institute Co., Ltd. romanized | 国药准字H20223049 | 0.05%(150ml:75mg) | Category B | XR06AEZ066X001020100371 | NHSA |
| Jiangsu Han Chen Pharma Co., Ltd. romanized | 国药准字H20183398 | 10ml:5mg | Category B | XR06AEZ066X001020101442 | NHSA |
| Sichuan Da Zhong Pharmaceutical Co., Ltd. romanized | 国药准字H20203222 | 0.05%(150ml:75mg) | Category B | XR06AEZ066X001020102132 | NHSA |
| Ya Bao Pharma Sichuan Pharmaceutical Co., Ltd. romanized | 国药准字H20265413 | 150ml:75mg | Category B | XR06AEZ066X001020102281 | NHSA |
| Zhejiang He Li Xin Jian Pharma Co., Ltd. romanized | 国药准字H20223974 | 0.05%(150ml:75mg) | Category B | XR06AEZ066X001020104670 | NHSA |
| Hunan Jiudian Pharmaceutical Co., Ltd | 国药准字H20183089 | 10ml:5mg | Category B | XR06AEZ066X001020104942 | NHSA |
| Hua Yi Tai Kang Pharma Co., Ltd. romanized | 国药准字H20183156 | 0.05%(150ml:75mg) | Category B | XR06AEZ066X001020105819 | NHSA |
| Bei Da Pharmaceuticals Co., Ltd. romanized | 国药准字H20244195 | 10ml:5mg | Category B | XR06AEZ066X001020109586 | NHSA |
| Chongqing Sheng Kai Pharmaceutical Co., Ltd. romanized | 国药准字H20253352 | 150ml:75mg | Category B | XR06AEZ066X001020179299 | NHSA |
| Shandong Zhi Tai Pharmaceuticals Technology Co., Ltd. romanized | 国药准字H20254369 | 75ml:37.5mg | Category B | XR06AEZ066X001020183094 | NHSA |
| Anhui Si Huan Ke Bao Pharmaceutical Co., Ltd. romanized | 国药准字H20264893 | 10ml:5mg | Category B | XR06AEZ066X001020183595 | NHSA |
| Jiangsu Han Chen Pharma Co., Ltd. romanized | 国药准字H20183398 | 10ml:5mg | Category B | XR06AEZ066X001020201442 | NHSA |
| Bei Da Pharmaceuticals Co., Ltd. romanized | 国药准字H20244195 | 10ml:5mg | Category B | XR06AEZ066X001020209586 | NHSA |
| Anhui Si Huan Ke Bao Pharmaceutical Co., Ltd. romanized | 国药准字H20264893 | 10ml:5mg | Category B | XR06AEZ066X001020283595 | NHSA |
| Jiangsu Han Chen Pharma Co., Ltd. romanized | 国药准字H20183398 | 10ml:5mg | Category B | XR06AEZ066X001020301442 | NHSA |
| Anhui Si Huan Ke Bao Pharmaceutical Co., Ltd. romanized | 国药准字H20264893 | 10ml:5mg | Category B | XR06AEZ066X001020383595 | NHSA |
| Jiangsu Han Chen Pharma Co., Ltd. romanized | 国药准字H20183398 | 10ml:5mg | Category B | XR06AEZ066X001020401442 | NHSA |
| Anhui Si Huan Ke Bao Pharmaceutical Co., Ltd. romanized | 国药准字H20264893 | 10ml:5mg | Category B | XR06AEZ066X001020483595 | NHSA |
| Jiangsu Han Chen Pharma Co., Ltd. romanized | 国药准字H20183398 | 10ml:5mg | Category B | XR06AEZ066X001020501442 | NHSA |
| Jiangsu Han Chen Pharma Co., Ltd. romanized | 国药准字H20183398 | 10ml:5mg | Category B | XR06AEZ066X001020601442 | NHSA |
| Jiangsu Han Chen Pharma Co., Ltd. romanized | 国药准字H20183398 | 10ml:5mg | Category B | XR06AEZ066X001030101442 | NHSA |
| Hunan Jiudian Pharmaceutical Co., Ltd | 国药准字H20183089 | 10ml:5mg | Category B | XR06AEZ066X001030104942 | NHSA |
| Hua Yi Tai Kang Pharma Co., Ltd. romanized | 国药准字H20183155 | 0.05%(10ml:5mg) | Category B | XR06AEZ066X001030105819 | NHSA |
| Anhui Si Huan Ke Bao Pharmaceutical Co., Ltd. romanized | 国药准字H20264892 | 5ml:2.5mg | Category B | XR06AEZ066X001030183595 | NHSA |
| Anhui Si Huan Ke Bao Pharmaceutical Co., Ltd. romanized | 国药准字H20264892 | 5ml:2.5mg | Category B | XR06AEZ066X001030283595 | NHSA |
| Anhui Si Huan Ke Bao Pharmaceutical Co., Ltd. romanized | 国药准字H20264892 | 5ml:2.5mg | Category B | XR06AEZ066X001030383595 | NHSA |
| Anhui Si Huan Ke Bao Pharmaceutical Co., Ltd. romanized | 国药准字H20264892 | 5ml:2.5mg | Category B | XR06AEZ066X001030483595 | NHSA |
| Jiangsu Han Chen Pharma Co., Ltd. romanized | 国药准字H20183398 | 10ml:5mg | Category B | XR06AEZ066X001040101442 | NHSA |
| Hua Yi Tai Kang Pharma Co., Ltd. romanized | 国药准字H20183155 | 0.05%(10ml:5mg) | Category B | XR06AEZ066X001040105819 | NHSA |
| Hua Yi Tai Kang Pharma Co., Ltd. romanized | 国药准字H20183155 | 0.05%(10ml:5mg) | Category B | XR06AEZ066X001040205819 | NHSA |
| Hua Yi Tai Kang Pharma Co., Ltd. romanized | 国药准字H20183155 | 0.05%(10ml:5mg) | Category B | XR06AEZ066X001050105819 | NHSA |
| Hua Yi Tai Kang Pharma Co., Ltd. romanized | 国药准字H20183155 | 0.05%(10ml:5mg) | Category B | XR06AEZ066X001050305819 | NHSA |
| Jiangsu Han Chen Pharma Co., Ltd. romanized | 国药准字H20183398 | 10ml:5mg | Category B | XR06AEZ066X001060101442 | NHSA |
| Hua Yi Tai Kang Pharma Co., Ltd. romanized | 国药准字H20183155 | 0.05%(10ml:5mg) | Category B | XR06AEZ066X001060105819 | NHSA |
| Jiangsu Han Chen Pharma Co., Ltd. romanized | 国药准字H20183398 | 10ml:5mg | Category B | XR06AEZ066X001060201442 | NHSA |
| Jiangsu Han Chen Pharma Co., Ltd. romanized | 国药准字H20183398 | 10ml:5mg | Category B | XR06AEZ066X001070101442 | NHSA |
| Jiangsu Han Chen Pharma Co., Ltd. romanized | 国药准字H20183398 | 10ml:5mg | Category B | XR06AEZ066X001080101442 | NHSA |
| Jiangsu Han Chen Pharma Co., Ltd. romanized | 国药准字H20183398 | 10ml:5mg | Category B | XR06AEZ066X001090101442 | NHSA |
| Jiangsu Han Chen Pharma Co., Ltd. romanized | 国药准字H20183398 | 10ml:5mg | Category B | XR06AEZ066X001100101442 | NHSA |
Approval numbers and companies are deduplicated separately; packaging records remain individually listed. An empty insurance class means it is unstated. NHSA codes supply no approval date and do not establish the outcome of an acceptance number.
Loaded records: 5 filings and 3 distinct first applicants.
Generic 5
| Company / applicant | Acceptance number | Application type | Accepted | Strength / specification | View source |
|---|---|---|---|---|---|
| Hainan Wan Wei Pharmaceutical Co., Ltd. romanized | CYHS2600450 | Generic | 2026/02/11 | Not stated by source | CDE |
| Chongqing He Ping Pharmaceutical Co., Ltd. romanized | CYHS2504113 | Generic | 2025/11/29 | Not stated by source | CDE |
| Chongqing He Ping Pharmaceutical Co., Ltd. romanized | CYHS2504112 | Generic | 2025/11/29 | Not stated by source | CDE |
| Guangdong Nan Guo Pharma Co., Ltd. romanized | CYHS2602792 | Generic | 2026/11/12 | Not stated by source | CDE |
| Guangdong Nan Guo Pharma Co., Ltd. romanized | CYHS2602791 | Generic | 2026/11/12 | Not stated by source | CDE |
Loaded records: 3 filings and 2 distinct first applicants.
| Company / applicant | Acceptance number | Application type | Accepted | Strength / specification | View source |
|---|---|---|---|---|---|
| Hainan Wan Wei Pharmaceutical Co., Ltd. romanized | CYHS2600450 | Generic | 2026/02/11 | Not stated by source | CDE |
| Guangdong Nan Guo Pharma Co., Ltd. romanized | CYHS2602792 | Generic | 2026/11/12 | Not stated by source | CDE |
| Guangdong Nan Guo Pharma Co., Ltd. romanized | CYHS2602791 | Generic | 2026/11/12 | Not stated by source | CDE |
Non-component matches: 12 companies with A status and 2 I-status records. Component matches are listed separately and excluded from these counts.
| Name | Company / applicant | Registration number | Status | Name match | Source update date | View source |
|---|---|---|---|---|---|---|
| 盐酸左西替利嗪 · No verified English name | Qi Dong Dong Yue Pharma Co., Ltd. romanized | Y20260000499 | I | Exact ingredient | 2026/08/18 | CDE |
| 盐酸左西替利嗪 · No verified English name | Glochem Industries Private Limited | Y20240001166 | A | Exact ingredient | 2026/10/29 | CDE |
| 盐酸左西替利嗪 · No verified English name | Hubei Mei Lin Pharma Co., Ltd. romanized | Y20200001504 | A | Exact ingredient | 2026/01/29 | CDE |
| 盐酸左西替利嗪 · No verified English name | Chongqing Hua Bang Sheng Kai Pharmaceutical Co., Ltd. romanized | Y20190009441 | A | Exact ingredient | — | CDE |
| 盐酸左西替利嗪 · No verified English name | Granules India Limited | Y20190009207 | A | Exact ingredient | 2024/11/29 | CDE |
| 盐酸左西替利嗪 · No verified English name | Zhejiang Yong Ning Pharma Co., Ltd. romanized | Y20190007284 | A | Exact ingredient | 2023/05/25 | CDE |
| 盐酸左西替利嗪 · No verified English name | Fu An Pharma Group Ningbo Tian Heng Pharmaceutical Co., Ltd. romanized | Y20190006460 | A | Exact ingredient | 2025/09/02 | CDE |
| 盐酸左西替利嗪 · No verified English name | Jiangsu Heng Rui Pharmaceuticals Co., Ltd. romanized | Y20190006270 | A | Exact ingredient | 2025/10/16 | CDE |
| 盐酸左西替利嗪 · No verified English name | Suzhou Dong Rui Pharmaceutical Co., Ltd. romanized | Y20190005049 | A | Exact ingredient | 2025/06/28 | CDE |
| 盐酸左西替利嗪 · No verified English name | Hunan Jiu Dian Hong Yang Pharmaceutical Co., Ltd. romanized | Y20190004640 | A | Exact ingredient | 2025/07/28 | CDE |
| 盐酸左西替利嗪 · No verified English name | Zhejiang Hai Li Sheng Pharmaceutical Co., Ltd. romanized | Y20190003254 | A | Exact ingredient | — | CDE |
| 盐酸左西替利嗪 · No verified English name | Shanghai Qing Song Pharmaceutical Co., Ltd. romanized | Y20190001278 | A | Exact ingredient | — | CDE |
| 盐酸左西替利嗪 · No verified English name | Chongqing Sheng Kai Pharmaceutical Co., Ltd. romanized | Y20170002219 | A | Exact ingredient | 2025/04/17 | CDE |
| 盐酸左西替利嗪 · No verified English name | Glochem Industries Limited | Y20170001135 | I | Exact ingredient | — | CDE |
A/I are source statuses. Matching uses exact ingredients, salt-normalized names and maintained combination components, without fuzzy matching. A-status companies are deduplicated by the first registered company. Components are excluded from headline counts; the register does not identify the associated formulation.
Last 90 days, ordered by fact date. Marketing approvals, trial registrations, supplements, notices and review changes are labelled separately.
Trial registration does not mean an application will follow.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
NHSA edition maintained to 2026-10-23; latest successful catalogue check: 2026/11/16 06:35. NHSA records lack approval dates; only an earlier edition or observation establishes precedence.
CYHS2602792
Fact date: 2026/11/12 · Site observation date: 2026/11/13
View source ↗CYHS2602791
Fact date: 2026/11/12 · Site observation date: 2026/11/13
View source ↗CYHB2601792
Fact date: 2026/10/23 · Site observation date: 2026/10/23
Accepted: 2026/09/22
not on the CDE under-review list in this snapshot; NMPA published approval-document delivery for this acceptance number on 2026/10/23 (approval no.: —; approval date: 2026/10/21); this is a supplemental application, not counted as a new marketing approval · NMPA source · row 26
NMPA · Table row 26 ↗ View source ↗CYHB2601791
Fact date: 2026/10/23 · Site observation date: 2026/10/23
Accepted: 2026/09/22
not on the CDE under-review list in this snapshot; NMPA published approval-document delivery for this acceptance number on 2026/10/23 (approval no.: —; approval date: 2026/10/21); this is a supplemental application, not counted as a new marketing approval · NMPA source · row 25
NMPA · Table row 25 ↗ View source ↗CYHB2601792
Fact date: 2026/10/21 · Publication date: 2026/10/23 · Site observation date: 2026/11/03
Supplemental application; excluded from new marketing approvals.
View source · Table row 26 ↗CYHB2601791
Fact date: 2026/10/21 · Publication date: 2026/10/23 · Site observation date: 2026/11/03
Supplemental application; excluded from new marketing approvals.
View source · Table row 25 ↗CYHB2601792
Fact date: 2026/09/22 · Site observation date: 2026/10/22
View source ↗CYHB2601791
Fact date: 2026/09/22 · Site observation date: 2026/10/22
View source ↗Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
The fully loaded edition was maintained to 2026-10-23. Publication lags maintenance: the verified 2026-10-16 edition was published on 10-28, a 12-day gap. This is not a fixed lag for every edition.
First index-page publication dates: 2026-10-29 to 2026-11-13; 0 pages pending. Covers loaded notices only, not a complete historical approval database.
Daily collection reads new registrations. Backfill covers registration numbers from 2025 onward (CTR2025/CTR2026), not first-publication years. States are dated observations; revisions are not tracked.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
Public-product searches scanned: 11/30; discovered pending details: 9. Record counts in unscanned portions remain unknown.
Filings are counted by acceptance number and filing companies by first applicant. Strengths may have separate applications. Drug names are normalized only for width and whitespace; distinct generic names, dosage forms and combinations remain separate. Unstated strengths are marked. Company counts from different sources must not be added together.
Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.
Free follow
Up to 3 drugs per email address, in one weekly digest. Starts after email confirmation; unsubscribe at any time.
Subscriptions
US$200
Billed every month
Sign in to subscribeUS$540
Billed every three months
US$180 per month
Sign in to subscribeUS$1,920
Billed every year
US$160 per month
Sign in to subscribeSeparate one-time purchase
Full table and CSV export for 12 months from payment, with monthly data updates. No automatic renewal.
Subscriptions and comparison-table access are purchased separately. Neither includes the other.
Billed by Creem, our merchant of record · Terms · Refund policy
No account needed.
Covers all drugs in the loaded CDE records, not only this one: weekly acceptance counts, top-10 lists and definitions. View the latest report